Online citations, reference lists, and bibliographies.
← Back to Search

The Diagnostic Role Of PTEN And ARID1A In Serous Effusions

B. Davidson, M. Pinamonti, D. Cuevas, A. Holth, P. Zeppa, T. Hager, J. Wohlschlaeger, M. Tötsch
Published 2017 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
The aim of this study was to analyze the diagnostic role of PTEN and ARID1A in effusion cytology. Effusions (n = 279), consisting of 226 carcinomas (70 ovarian, 64 breast, 36 lung, and 15 uterine corpus carcinomas; 41 carcinomas of other origin) and 53 malignant mesotheliomas, were analyzed for PTEN and ARID1A expression using immunohistochemistry. PTEN was preserved in 166 (59%) tumors, partially lost in 38 (14%), and absent in 75 (27%), with lower expression in malignant mesotheliomas compared to carcinomas, though not significantly (p = 0.084). ARID1A was preserved in 243 (88%) tumors, partially lost in 18 (6%), and absent in 18 (6%). The majority of tumors with absent ARID1A were ovarian carcinomas, predominantly of clear cell or low-grade serous type. Reactive mesothelial cells in carcinoma specimens were uniformly positive for both proteins. ARID1A mutation analysis showed no mutations in eight analyzed specimens negative by immunohistochemistry. Loss of PTEN and ARID1A expression is highly specific for malignancy in effusion pathology. Loss of PTEN is not informative of organ of origin, whereas absence of ARID1A should raise suspicion of an ovarian primary.
This paper references
10.1111/his.12349
Ovarian carcinoma histotype determination is highly reproducible, and is improved through the use of immunohistochemistry
M. Köbel (2014)
10.1007/s10120-016-0627-z
PTEN loss is associated with a poor response to trastuzumab in HER2-overexpressing gastroesophageal adenocarcinoma
Yasunori Deguchi (2016)
10.1002/DC.20771
MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells
B. Davidson (2007)
10.1158/1055-9965.EPI-13-0391
Biomarker-Based Ovarian Carcinoma Typing: A Histologic Investigation in the Ovarian Tumor Tissue Analysis Consortium
M. Köbel (2013)
10.1016/j.immuni.2017.02.001
Loss of PTEN Is Associated with Resistance to Anti‐PD‐1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma
Suzanne George (2017)
10.1016/j.humpath.2015.08.020
MMP-7 is a highly specific negative marker for benign and malignant mesothelial cells in serous effusions.
B. Davidson (2016)
10.1158/1535-7163.MCT-15-0554
Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib
R. Miller (2016)
10.1097/PAS.0b013e3181b6bde3
Tenascin-X is a Novel Diagnostic Marker of Malignant Mesothelioma
Y. Yuan (2009)
10.1007/978-0-85729-697-9
[Serous effusions].
B. Davidson (2000)
Value of PAX 8 , PAX 2 , napsin A , carbonic anhydrase IX , and claudin4 immunostaining in distinguishing pleural epithelioid mesothelioma frommetastatic renal cell carcino
NG Ordóñez (2013)
10.1136/jclinpath-2015-203211
Peritoneal malignant mesothelioma (PMM), and primary peritoneal serous carcinoma (PPSC) and reactive mesothelial hyperplasia (RMH) of the peritoneum. Immunohistochemical and fluorescence in situ hybridisation (FISH) analyses
T. Kawai (2016)
Comprar Serous Effusions | Michael, Claire W. | 9780857296962 | Springer
C. Michael (2011)
10.1038/modpathol.2013.34
Value of PAX8, PAX2, napsin A, carbonic anhydrase IX, and claudin-4 immunostaining in distinguishing pleural epithelioid mesothelioma from metastatic renal cell carcinoma
N. Ordóñez (2013)
10.1158/1078-0432.CCR-15-0965
Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer
S. Loibl (2016)
10.18632/oncotarget.10921
Loss of ARID1A expression leads to sensitivity to ROS-inducing agent elesclomol in gynecologic cancer cells
Suet-Yan Kwan (2016)
10.2217/fon.15.45
Molecular pathogenesis of ovarian clear cell carcinoma.
I. Gounaris (2015)
10.1007/s13277-015-3258-9
Tau and PTEN status as predictive markers for response to trastuzumab and paclitaxel in patients with HER2-positive breast cancer
Dong-Hoe Koo (2015)
10.1038/modpathol.2012.200
Value of PAX8, PAX2, claudin-4, and h-caldesmon immunostaining in distinguishing peritoneal epithelioid mesotheliomas from serous carcinomas
N. Ordóñez (2013)
10.1002/cncy.21392
Claudin‐4 immunohistochemistry is highly effective in distinguishing adenocarcinoma from malignant mesothelioma in effusion cytology
V. Jo (2014)
10.1371/journal.pone.0062483
ARID1A Alterations Are Associated with FGFR3-Wild Type, Poor-Prognosis, Urothelial Bladder Tumors
Cristina Balbás-Martínez (2013)
10.1002/cncy.21353
Hepatocyte nuclear factor‐1β is not a specific marker of clear cell carcinoma in serous effusions
B. Davidson (2014)
10.1517/14728222.2015.1062879
Potential therapeutic targets in ARID1A-mutated cancers
B. Bitler (2015)
10.1097/PAI.0b013e3182366531
Is PAX2 a Reliable Marker in Differentiating Diffuse Malignant Mesotheliomas of Peritoneum From Serous Carcinomas of Müllerian Origin?
F. Gao (2012)
10.1002/ijc.30848
Mutation in the FGFR1 tyrosine kinase domain or inactivation of PTEN is associated with acquired resistance to FGFR inhibitors in FGFR1‐driven leukemia/lymphomas
J. Cowell (2017)
10.1200/JCO.2016.67.9084
Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma.
M. Voss (2016)
10.1097/PAS.0b013e3181da7687
PAX8 Reliably Distinguishes Ovarian Serous Tumors From Malignant Mesothelioma
Anna R. Laury (2010)
10.1038/ncomms13837
ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A
C. Williamson (2016)
10.1007/s00018-017-2500-6
PTEN proteoforms in biology and disease
P. Malaney (2017)
10.1093/annonc/mdw552
Targeting chromatin defects in selected solid tumors based on oncogene addiction, synthetic lethality and epigenetic antagonism.
D. Morel (2017)
10.1016/j.humpath.2013.10.018
Optimal protocol for PTEN immunostaining; role of analytical and preanalytical variables in PTEN staining in normal and neoplastic endometrial, breast, and prostatic tissues.
O. Maiques (2014)
10.3892/or.2015.4421
ARID1A gene mutation in ovarian and endometrial cancers (Review)
T. Takeda (2016)
10.1016/j.humpath.2016.08.005
CD24 is highly useful in differentiating high-grade serous carcinoma from benign and malignant mesothelial cells.
B. Davidson (2016)
10.1038/modpathol.2011.208
Clinical Assessment of PTEN Loss in Endometrial Carcinoma: Immunohistochemistry Out-Performs Gene Sequencing
B. Djordjevic (2012)
10.1097/PGP.0b013e3182230d00
Pathologic Scoring of PTEN Immunohistochemistry in Endometrial Carcinoma is Highly Reproducible
K. Garg (2012)
10.1016/j.humpath.2015.12.012
Loss of BAP1 expression is very rare in peritoneal and gynecologic serous adenocarcinomas and can be useful in the differential diagnosis with abdominal mesothelioma.
J. Andrici (2016)
10.1101/cshperspect.a026930
The Many Roles of BAF (mSWI/SNF) and PBAF Complexes in Cancer.
C. Hodges (2016)
10.1007/s00428-007-0448-x
Claudin 4 identifies a wide spectrum of epithelial neoplasms and represents a very useful marker for carcinoma versus mesothelioma diagnosis in pleural and peritoneal biopsies and effusions
F. Facchetti (2007)
10.1309/V025QRN3R9CJGNPX
The diagnostic role of claudins in serous effusions.
L. Kleinberg (2007)
10.1158/1078-0432.CCR-15-2996
Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance
K. Berns (2016)
Hepatocyte nuclear factor-1β is not a specific marker of clear cell carcinoma in serous effusions. Cancer Cytopathol 122(2):153–158
B Davidson (2014)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar